Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3682708 | 1.00 | MEN1 (0.56) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL186729 | 1.00 | MEN1 (0.56) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL8430294 | 0.91 | MEN1 (0.47) | MEN1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL8430296 | 0.91 | MEN1 (0.47) | MEN1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL16516485 | 0.91 | MEN1 (0.49) | MEN1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL16516487 | 0.91 | MEN1 (0.49) | MEN1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL16516488 | 0.91 | MEN1 (0.49) | MEN1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL25669721 | 0.88 | EPHX1 (0.49) | MEN1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL12394376 | 0.86 | LMNA (0.49) | MEN1KMT2ALMNAALDH1A1AKR1C3 | |
| SCHEMBL7522147 | 0.85 | MEN1 (0.47) | MEN1KMT2ALMNAALDH1A1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0592552-B1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES | DU PONT (US) | 1997-05-28 | — | — | EP | claimed |
| CN-122036790-A | Chiral phosphine-acyclic phosphoramidite ligand, preparation method and application thereof | 中国科学院大连化学物理研究所 | 2026-05-15 | — | — | CN | disclosed |
| CN-113121615-B | Ferrocene boracic chiral diphosphine ligand and preparation method and application thereof | 南方科技大学 | 2023-02-17 | — | — | CN | disclosed |
| CN-111018918-B | Metal complex, intermediate, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2022-10-04 | — | — | CN | disclosed |
| US-11325875-B2 | Compound having chiral spirobiindane skeleton and preparation method therefor | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2022-05-10 | — | — | US | disclosed |
| EP-3865494-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-08-18 | — | — | EP | disclosed |
| CN-113121615-A | Ferrocene boracic chiral diphosphine ligand and preparation method and application thereof | 南方科技大学 | 2021-07-16 | — | — | CN | disclosed |
| CN-111868065-A | C-sterically hindered P-chirally derived organophosphorus compounds | 勃艮第大学 | 2020-10-30 | — | — | CN | disclosed |
| CN-108339571-A | P- chiral source organic phosphorus compounds | 国家科学研究中心 | 2018-07-31 | — | — | CN | disclosed |
| CN-103797020-B | P-chirality source organic phosphorus compound | 国家科学研究中心 | 2018-01-30 | — | — | CN | disclosed |
| CN-1064047-C | Chiral phosphine nitride-phosphine oxide double coordinate-bond ligand complex and the synthesis and application thereof | CHENGDU ORGANIC CHEM INST (CN) | 2001-04-04 | — | — | CN | disclosed |
| CN-1059211-C | Chirality epoxy phosphine ligand compound and its synthesis and application | CHENGDU ORGANIC CHEM INST (CN) | 2000-12-06 | — | — | CN | disclosed |
| US-6037493-A | Optically active diphosphines, preparation thereof according to a process for the resolution of the racemic mixture and use thereof | RHONE-POULENC CHIMIE (FR) | 2000-03-14 | — | — | US | disclosed |
| US-5783738-A | Optically active diphosphines, preparation thereof according to a process for the resolution of the racemic mixture and use thereof | RHONE-POULENC CHIMIE (FR) | 1998-07-21 | — | — | US | disclosed |
| CN-1180707-A | Chirality epoxy phosphine ligand compound and its synthesis and application | CHENGDU ORGANIC CHEM INST (CN) | 1998-05-06 | — | — | CN | disclosed |
| CN-1168888-A | Chiral phosphine nitride-phosphine oxide double coordinate-bond ligand complex and the synthesis and application thereof | CHENGDU ORGANIC CHEM INST (CN) | 1997-12-31 | — | — | CN | disclosed |
| EP-0198397-B1 | METHOD OF PRODUCING L-PHENYLALANINE | KURARAY CO., LTD. (JP) | 1993-01-07 | — | — | EP | disclosed |
| US-4743547-A | PURITY, ENZYME HYDROLYSIS | KURARAY CO., LTD. (JP) | 1988-05-10 | — | — | US | disclosed |
| US-4654176-A | Sulphonated chiral phosphines, their preparation and their use | RHONE-POULENC SANTE (FR) | 1987-03-31 | — | — | US | disclosed |
| EP-0198397-A2 | Method of producing L-phenylalanine | KURARAY CO., LTD. (JP) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325875-B2 | Compound having chiral spirobiindane skeleton and preparation method therefor | REN, VKORC1, NR3C2 | MEN1 1056/4885KMT2A 3799/4885LMNA 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.